Cover Image

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: an expert consensus statement from ERKNet and ESPN

Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current...

Full description

Saved in:
Bibliographic Details
Main Authors: Reijman, M. Doortje (Author) , Kusters, D. Meeike (Author) , Groothoff, Jaap W. (Author) , Arbeiter, Klaus (Author) , Dann, Eldad J. (Author) , de Boer, Lotte M. (Author) , de Ferranti, Sarah D. (Author) , Gallo, Antonio (Author) , Greber-Platzer, Susanne (Author) , Hartz, Jacob (Author) , Hudgins, Lisa C. (Author) , Ibarretxe, Daiana (Author) , Kayikcioglu, Meral (Author) , Klingel, Reinhard (Author) , Kolovou, Genovefa D. (Author) , Oh, Jun (Author) , Planken, R. Nils (Author) , Stefanutti, Claudia (Author) , Taylan, Christina (Author) , Wiegman, Albert (Author) , Schmitt, Claus P. (Author)
Format: Article (Journal)
Language:English
Published: May 2024
In: Atherosclerosis
Year: 2024, Volume: 392, Pages: 1-13
ISSN:1879-1484
DOI:10.1016/j.atherosclerosis.2024.117525
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.atherosclerosis.2024.117525
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0021915024000856
Get full text
Author Notes:M. Doortje Reijman, D. Meeike Kusters, Jaap W. Groothoff, Klaus Arbeiter, Eldad J. Dann, Lotte M. de Boer, Sarah D. de Ferranti, Antonio Gallo, Susanne Greber-Platzer, Jacob Hartz, Lisa C. Hudgins, Daiana Ibarretxe, Meral Kayikcioglu, Reinhard Klingel, Genovefa D. Kolovou, Jun Oh, R. Nils Planken, Claudia Stefanutti, Christina Taylan, Albert Wiegman, Claus Peter Schmitt
Description
Summary:Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is used for decades, lowering serum LDL-C levels by more than 70% directly after the treatment. Data on the use of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia mainly consists of case-reports and case-series, precluding strong evidence-based guidelines. We present a consensus statement on lipoprotein apheresis in children based on the current available evidence and opinions from experts in lipoprotein apheresis from over the world. It comprises practical statements regarding the indication, methods, treatment goals and follow-up of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia and on the role of lipoprotein(a) and liver transplantation.
Item Description:Online verfügbar 27 March 2024, Version des Artikels 9 April 2024
Gesehen am 29.11.2024
Physical Description:Online Resource
ISSN:1879-1484
DOI:10.1016/j.atherosclerosis.2024.117525

Similar Items